Literature DB >> 6996481

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

H M Shulman, K M Sullivan, P L Weiden, G B McDonald, G E Striker, G E Sale, R Hackman, M S Tsoi, R Storb, E D Thomas.   

Abstract

This study of chronic graft-versus-host disease (GVHD) describes the clinical, pathologic and laboratory features, and the causes of morbidity and mortality in 20 patients who received allogeneic marrow transplants from HLA identical sibling donors. Chronic GVHD is a pleiotrophic syndrome with variability in the time of onset, organ systems involved and rate of progression. The clinical-pathologic features resemble an overlap of several collagen vascular diseases with frequent involvement of the skin, liver, eyes, mouth, upper respiratory tract, esophagus and less frequent involvement of the serosal surfaces, lower gastrointestinal tract and skeletal muscles. Major causes of morbidity are scleroderma with contractures and ulceration, dry eyes and mouth, pulmonary insufficiency and wasting. Chronic GVHD has features of immune dysregulation with elevated levels of eosinophils, circulating autoantibodies, hypergammaglobulinemia and plasmacytosis of viscera and lymph nodes. In this study, three patients had limited chronic GVHD with relatively favorable prognosis characterized by localized skin involvement and/or hepatic disease without chronic aggressive histology. Most patients, however, had extensive disease with a progressive course. Survival was largely determined by the presence or absence of serious recurrent bacterial infections. The over-all severity of disease was best assessed by using the Karnofsky performance rating.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6996481     DOI: 10.1016/0002-9343(80)90380-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  527 in total

1.  Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.

Authors:  M Binks; J R Passweg; D Furst; P McSweeney; K Sullivan; C Besenthal; J Finke; H H Peter; J van Laar; F C Breedveld; W E Fibbe; D Farge; E Gluckman; F Locatelli; A Martini; F van den Hoogen; L van de Putte; A V Schattenberg; R Arnold; P A Bacon; P Emery; I Espigado; B Hertenstein; F Hiepe; A Kashyap; I Kötter; A Marmont; A Martinez; M J Pascual; A Gratwohl; H G Prentice; C Black; A Tyndall
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

Review 2.  Management of graft-versus-host disease in paediatric bone marrow transplant recipients.

Authors:  M Zecca; F Locatelli
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

3.  Using related donors other than genotypically HLA-matched siblings in allogeneic hematopoietic stem cell transplantation for hematologic disease: a single institution experience in Japan.

Authors:  Akira Tomonari; Tohru Iseki; Jun Ooi; Satoshi Takahashi; Koji Ishii; Tsutomu Takahashi; Motohiro Shindo; Fumitaka Nagamura; Kaoru Uchimaru; Hitomi Nagayama; Naoki Shirafuji; Arinobu Tojo; Kenzaburo Tani; Shigetaka Asano
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

4.  Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?

Authors:  Mitchell Sabloff; Ronald M Sobecks; Kwang Woo Ahn; Xiaochun Zhu; Marcos de Lima; Jennifer R Brown; Yoshihiro Inamoto; H Kent Holland; Mahmoud D Aljurf; Mary J Laughlin; Rammurti T Kamble; Jack W Hsu; Baldeep M Wirk; Matthew Seftel; Ian D Lewis; Mukta Arora; Edwin P Alyea; Matt E Kalaycio; Jorge Cortes; Richard T Maziarz; Robert Peter Gale; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2013-12-07       Impact factor: 5.742

5.  Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma.

Authors:  Mehdi Hamadani; Wael Saber; Kwang Woo Ahn; Jeanette Carreras; Mitchell S Cairo; Timothy S Fenske; Robert Peter Gale; John Gibson; Gregory A Hale; Parameswaran N Hari; Jack W Hsu; David J Inwards; Rammurti T Kamble; Anderas Klein; Dipnarine Maharaj; David I Marks; David A Rizzieri; Bipin N Savani; Harry C Schouten; Edmund K Waller; Baldeep Wirk; Ginna G Laport; Silvia Montoto; David G Maloney; Hillard M Lazarus
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-01       Impact factor: 5.742

6.  GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia.

Authors:  Rohtesh S Mehta; Shernan G Holtan; Tao Wang; Michael T Hemmer; Stephen R Spellman; Mukta Arora; Daniel R Couriel; Amin M Alousi; Joseph Pidala; Hisham Abdel-Azim; Ibrahim Ahmed; Mahmoud Aljurf; Medhat Askar; Jeffery J Auletta; Vijaya Bhatt; Christopher Bredeson; Saurabh Chhabra; Shahinaz Gadalla; James Gajewski; Robert Peter Gale; Usama Gergis; Peiman Hematti; Gerhard C Hildebrandt; Yoshihiro Inamoto; Carrie Kitko; Pooja Khandelwal; Margaret L MacMillan; Navneet Majhail; David I Marks; Parinda Mehta; Taiga Nishihori; Richard F Olsson; Attaphol Pawarode; Miguel Angel Diaz; Tim Prestidge; Muna Qayed; Hemalatha Rangarajan; Olle Ringden; Ayman Saad; Bipin N Savani; Sachiko Seo; Ami Shah; Niketa Shah; Kirk R Schultz; Melhem Solh; Thomas Spitzer; Jeffrey Szer; Takanori Teshima; Leo F Verdonck; Kirsten M Williams; Baldeep Wirk; John Wagner; Jean A Yared; Daniel J Weisdorf
Journal:  Blood Adv       Date:  2019-05-14

7.  T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin.

Authors:  Ann A Jakubowski; Trudy N Small; James W Young; Nancy A Kernan; Hugo Castro-Malaspina; Katherine C Hsu; Miguel-Angel Perales; Nancy Collins; Christine Cisek; Michelle Chiu; Marcel R M van den Brink; Richard J O'Reilly; Esperanza B Papadopoulos
Journal:  Blood       Date:  2007-08-23       Impact factor: 22.113

8.  Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.

Authors:  Yoshihiro Inamoto; Fumihiko Kimura; Junya Kanda; Junichi Sugita; Kazuhiro Ikegame; Hideki Nakasone; Yasuhito Nannya; Naoyuki Uchida; Takahiro Fukuda; Kosuke Yoshioka; Yukiyasu Ozawa; Ichiro Kawano; Yoshiko Atsuta; Koji Kato; Tatsuo Ichinohe; Masami Inoue; Takanori Teshima
Journal:  Haematologica       Date:  2016-08-04       Impact factor: 9.941

9.  Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Monzr M Al Malki; Nitya Nathwani; Dongyun Yang; Saro Armenian; Sanjeet Dadwal; Jaroslava Salman; Sally Mokhtari; Thai Cao; Karamjeet Sandhu; Michelle Rouse; Matthew Mei; Haris Ali; Pablo Parker; Joseph Alvarnas; Eileen Smith; Margaret O Donnell; Guido Marcucci; David Snyder; Auayporn Nademanee; Stephen J Forman; Anthony Stein; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-09       Impact factor: 5.742

10.  A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies.

Authors:  Craig S Sauter; Joanne F Chou; Esperanza B Papadopoulos; Miguel-Angel Perales; Ann A Jakubowski; James W Young; Michael Scordo; Sergio Giralt; Hugo Castro-Malaspina
Journal:  Leuk Lymphoma       Date:  2014-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.